NO924830L - Intercellulaere adhesjonsbefordrende midler - Google Patents
Intercellulaere adhesjonsbefordrende midlerInfo
- Publication number
- NO924830L NO924830L NO92924830A NO924830A NO924830L NO 924830 L NO924830 L NO 924830L NO 92924830 A NO92924830 A NO 92924830A NO 924830 A NO924830 A NO 924830A NO 924830 L NO924830 L NO 924830L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- promoting agents
- compositions
- present
- selectin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Abstract
Foreliggende oppfinnelse vedrører blandinger og frem- gangsmåter for reduksjon eller kontroll av betennelse og for behandling av inflammatoriske sykdomsprosesser og andre pato- logiske tilstander befordret av intercellulær adhesjon. Blandinger som selektivt binder en selektinreseptor og som har minst en selektinbindende gruppe, tilveiebringes av den fore- liggende oppfinnelse. De selektinbindende grupper har den generelle formel: R,-Gal/31, 4 (Fucal, 3 ) GlcNAc- (R2) ¿ hvori R, er et oligosakkarid eller R3-R4~C(C02H)-, hvori R, og R. er de samme eller forskjellige og er -H, -Cl-C8-alkyl, -hydroksyl-Cl-C8-alkyl, -aryl-Cl-C8-alkyl, eller -alkoksy-Cl-C8-alkyl; hvori R., er /?l,3Gal, al,2Man, eller al,6GalNac og a er O eller 1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53885390A | 1990-06-15 | 1990-06-15 | |
US61931990A | 1990-11-28 | 1990-11-28 | |
US63239090A | 1990-12-21 | 1990-12-21 | |
PCT/US1991/003592 WO1991019501A1 (en) | 1990-06-15 | 1991-05-22 | Intercellular adhesion mediators |
PCT/US1991/004284 WO1991019502A1 (en) | 1990-06-15 | 1991-06-14 | Intercellular adhesion mediators |
Publications (2)
Publication Number | Publication Date |
---|---|
NO924830D0 NO924830D0 (no) | 1992-12-14 |
NO924830L true NO924830L (no) | 1993-02-08 |
Family
ID=27415280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO92924830A NO924830L (no) | 1990-06-15 | 1992-12-14 | Intercellulaere adhesjonsbefordrende midler |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0533834A1 (no) |
AU (2) | AU8007791A (no) |
BR (1) | BR9106556A (no) |
CA (1) | CA2084888A1 (no) |
FI (1) | FI925668A0 (no) |
HU (1) | HU216312B (no) |
IE (1) | IE912048A1 (no) |
IL (1) | IL98493A (no) |
NO (1) | NO924830L (no) |
NZ (1) | NZ238556A (no) |
SG (1) | SG52563A1 (no) |
WO (2) | WO1991019501A1 (no) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576305A (en) * | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US6387884B1 (en) | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
US6391857B1 (en) | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
US5211936A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a cite of inflammation utilizing elam-1 ligands site |
US5648344A (en) * | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
US5211937A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
US5807745A (en) * | 1991-03-11 | 1998-09-15 | New England Medical Center Hospitals, Inc. | Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component |
US6121233A (en) | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
WO1992018610A2 (en) * | 1991-04-19 | 1992-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for endothelial binding |
US5646123A (en) * | 1991-06-10 | 1997-07-08 | Alberta Research Council | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen |
CA2110495A1 (en) * | 1991-06-10 | 1992-12-23 | Robert M. Ippolito | Immunosuppressive and tolerogenic oligosaccharide derivatives |
GB9114657D0 (en) * | 1991-07-06 | 1991-08-21 | Antisoma Ltd | Diagnostic compounds |
WO1993005803A1 (en) * | 1991-09-25 | 1993-04-01 | Genetics Institute, Inc. | Anti-inflammatory selectin inhibitors |
EP0658344B1 (en) * | 1991-10-31 | 2000-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing tricyclic compound |
GB9208339D0 (en) * | 1992-04-15 | 1992-06-03 | Unilever Plc | Treatment composition |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
JPH08504171A (ja) * | 1992-05-28 | 1996-05-07 | セントコー・インコーポレーテッド | セレクチン結合のペプチド阻害剤 |
CA2136844A1 (en) * | 1992-05-28 | 1993-12-09 | George A. Heavner | Peptide inhibitors of selectin binding |
CA2100412A1 (en) * | 1992-07-15 | 1994-01-16 | Yutaka Yamada | Glycolipid derivatives |
JPH07509250A (ja) * | 1992-07-27 | 1995-10-12 | アメリカ合衆国 | 血液脳バリヤーへのリポソームの標的化 |
JPH08503694A (ja) * | 1992-09-08 | 1996-04-23 | セントコー・インコーポレーテッド | ペプチド系の細胞接着阻害物質 |
WO1994005314A1 (en) * | 1992-09-08 | 1994-03-17 | Centocor, Inc. | Peptide inhibitors of leukocyte adhesion |
CA2145881C (en) * | 1992-10-02 | 2000-12-19 | Richard Smith | Anti-inflammatory, tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides |
US5453272A (en) * | 1992-10-02 | 1995-09-26 | Alberta Research Council | Lectin derived carbohydrate binding-peptide |
US6406894B1 (en) | 1992-12-11 | 2002-06-18 | Glycorex Ab | Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks |
EP0601417A3 (de) * | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung |
US5710123A (en) * | 1992-12-18 | 1998-01-20 | Centocor, Inc. | Peptide inhibitors of selectin binding |
CA2157388C (en) * | 1993-03-01 | 1998-12-15 | Daniel P. Witt | Analogs for specific oligosaccharide-protein interactions and uses thereof |
EP0687684A4 (en) * | 1993-03-04 | 1998-03-04 | Kanto Ishi Pharma Co Ltd | COMPOUND ASSOCIATED WITH LEWIS SYSTEM, PROCESS FOR OBTAINING THIS COMPOUND AND ANTI-INFLAMMATORY |
US5811404A (en) * | 1993-05-14 | 1998-09-22 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
US5854218A (en) * | 1993-05-14 | 1998-12-29 | Cytel Corporation | Sialyl Lex analogues as inhibitors of cellular adhesion |
DE69430253T2 (de) | 1993-05-17 | 2002-11-14 | Avant Immunotherapeutics Inc | Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen |
US5976540A (en) * | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5856300A (en) * | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5789385A (en) * | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5837689A (en) * | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5658880A (en) * | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5750508A (en) * | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5679321A (en) * | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5559103A (en) * | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
WO1995013819A1 (en) * | 1993-11-19 | 1995-05-26 | The Regents Of The University Of California | Sulfated ligands for l-selectin and methods of preventing sulfate addition |
US5783693A (en) * | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
DE4408248A1 (de) * | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung |
DE4431280A1 (de) | 1994-09-02 | 1996-03-07 | Hoechst Ag | Verfahren zur Isolierung und Reinigung von nukleotidaktivierten Zuckern aus biologischen Quellen |
EP0783508A1 (en) * | 1994-09-20 | 1997-07-16 | PHARMACIA & UPJOHN COMPANY | The oligosaccharide structure of a ligand for e and p selectin |
DE4436164A1 (de) * | 1994-10-10 | 1996-04-11 | Hoechst Ag | Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion |
US5599915A (en) * | 1995-03-21 | 1997-02-04 | The Scripps Research Institute | Sialyl Lewis X mimetics |
US5614615A (en) * | 1995-03-21 | 1997-03-25 | The Scripps Research Institute | Sialyl Lewis X mimetics incorporating fucopeptides |
EP1428832A3 (en) * | 1995-08-03 | 2004-09-22 | The Board of Regents for the University of Oklahoma | Peptide and O-glycan inhibitors of selectin mediated inflammation |
EP0765884B1 (en) * | 1995-08-17 | 2004-04-14 | The Biomembrane Institute | Anti-inflammatory compound |
US5876715A (en) * | 1995-08-17 | 1999-03-02 | The Biomembrane Institute | Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof |
WO1997012892A1 (en) * | 1995-09-29 | 1997-04-10 | Glycim Oy | SYNTHETIC MULTIVALENT sLEX CONTAINING POLYLACTOSAMINES AND METHODS FOR USE |
WO1997014707A1 (en) * | 1995-10-18 | 1997-04-24 | Cytel Corporation | SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION |
WO1997018222A2 (en) * | 1995-11-13 | 1997-05-22 | Glycomed, Inc. | Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties |
EP0902681B1 (en) * | 1996-03-01 | 2002-05-22 | The Regents of the University of California | Inhibition of selectin binding |
WO1997037682A1 (en) * | 1996-04-10 | 1997-10-16 | Cytel Corporation | Nucleic acids encoding gdp-fucose pyrophosphorylase |
US5830871A (en) * | 1996-10-28 | 1998-11-03 | The Scripps Research Institute | Inhibitors of E-, P- and L-selectin binding |
EP0834572A3 (en) * | 1996-10-02 | 1999-08-25 | F. Hoffmann-La Roche Ag | Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives |
AU9073998A (en) | 1997-09-05 | 1999-03-29 | Glycim Oy | Synthetic divalent slex containing polylactosamines and methods for use |
EP2264166B1 (en) * | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
GB0015923D0 (en) * | 2000-06-30 | 2000-08-23 | Astrazeneca Ab | Methods |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7127357B1 (en) | 2000-12-08 | 2006-10-24 | The Salk Institute For Biological Studies | Crystal structure of WW domains and methods of use thereof |
CA2445826C (en) | 2001-05-02 | 2014-03-25 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
WO2002089819A1 (en) * | 2001-05-07 | 2002-11-14 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Glycoconjugates and uses thereof |
US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
ES2317010T3 (es) | 2003-05-30 | 2009-04-16 | Purdue Research Foundation | Metodo de diagnostico de la arterosclerosis. |
EP1655022A4 (en) * | 2003-08-01 | 2010-04-07 | Nat Inst Of Advanced Ind Scien | MEANS FOR THE TREATMENT OR DIAGNOSIS OF INFLAMMATORY DISEASES WITH A TARGETED LIPOSOM |
US7691810B2 (en) | 2003-10-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Method of producing recombinant antithrombin III composition |
JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
CN101287741B (zh) | 2005-09-02 | 2014-05-07 | 糖模拟物有限公司 | 异型双功能全选择素抑制剂 |
EP1940473A2 (en) | 2005-09-23 | 2008-07-09 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008148001A2 (en) | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
AU2009338190C1 (en) | 2009-01-22 | 2014-07-17 | Momenta Pharmaceuticals, Inc. | Galactose-alpha-1, 3-galactose-containing N-glycans in glycoprotein products derived from CHO cells |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
EP3296310A1 (en) | 2011-12-22 | 2018-03-21 | GlycoMimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
SI2928476T1 (en) | 2012-12-07 | 2018-06-29 | Glycomimetics, Inc. | COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS |
AU2015355136B2 (en) | 2014-12-03 | 2020-06-25 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
CA3009836A1 (en) | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
EP3497131B1 (en) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4. |
WO2018068010A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
JP7272956B2 (ja) | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体 |
WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
BR112020013198A2 (pt) | 2017-12-29 | 2020-12-01 | Glycomimetics, Inc. | inibidores heterobifuncionais de e-selectina e galectina-3 |
EP3761994A1 (en) | 2018-03-05 | 2021-01-13 | GlycoMimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2721900B2 (ja) * | 1988-09-18 | 1998-03-04 | 株式会社ニチレイ | 癌診断薬及びそれを用いた腫瘍マーカーの回収方法 |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
NZ240316A (en) * | 1990-10-25 | 1996-12-20 | Univ Michigan | Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells |
-
1991
- 1991-05-22 AU AU80077/91A patent/AU8007791A/en not_active Abandoned
- 1991-05-22 WO PCT/US1991/003592 patent/WO1991019501A1/en unknown
- 1991-06-13 IL IL9849391A patent/IL98493A/en not_active IP Right Cessation
- 1991-06-14 EP EP91912402A patent/EP0533834A1/en not_active Withdrawn
- 1991-06-14 BR BR919106556A patent/BR9106556A/pt not_active Application Discontinuation
- 1991-06-14 IE IE204891A patent/IE912048A1/en unknown
- 1991-06-14 SG SG1996006092A patent/SG52563A1/en unknown
- 1991-06-14 NZ NZ238556A patent/NZ238556A/en unknown
- 1991-06-14 HU HU9204091A patent/HU216312B/hu not_active IP Right Cessation
- 1991-06-14 CA CA002084888A patent/CA2084888A1/en not_active Abandoned
- 1991-06-14 WO PCT/US1991/004284 patent/WO1991019502A1/en not_active Application Discontinuation
- 1991-06-14 AU AU81029/91A patent/AU660931B2/en not_active Ceased
-
1992
- 1992-12-14 NO NO92924830A patent/NO924830L/no unknown
- 1992-12-14 FI FI925668A patent/FI925668A0/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1991019502A1 (en) | 1991-12-26 |
HUT69652A (en) | 1995-09-28 |
NO924830D0 (no) | 1992-12-14 |
CA2084888A1 (en) | 1991-12-16 |
FI925668A (fi) | 1992-12-14 |
WO1991019501A1 (en) | 1991-12-26 |
FI925668A0 (fi) | 1992-12-14 |
IL98493A (en) | 1998-12-06 |
AU660931B2 (en) | 1995-07-13 |
NZ238556A (en) | 1994-01-26 |
AU8102991A (en) | 1992-01-07 |
HU216312B (hu) | 1999-06-28 |
AU8007791A (en) | 1992-01-07 |
SG52563A1 (en) | 1998-09-28 |
IE912048A1 (en) | 1991-12-18 |
EP0533834A4 (no) | 1995-04-19 |
EP0533834A1 (en) | 1993-03-31 |
BR9106556A (pt) | 1991-12-26 |
HU9204091D0 (en) | 1993-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO924830L (no) | Intercellulaere adhesjonsbefordrende midler | |
NO932672L (no) | Monokloane antistoffer mot elam-1 og anvendelser derav | |
EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
TR199801041T2 (xx) | Kanabinoid resept�r afinitesine sahip olan 3-pirazolkarboksamid t�revleri. | |
FR2387264A1 (fr) | Composition elastomere photosensible | |
EP2520311A3 (en) | Method of treating hemolytic disease | |
DE3850485T2 (de) | Zeitmultiplexvermittlung für Mehrkanal-Verbindungen, welche zwei Zeitvermittlungsspeicher als Rahmenausgleicher verwendet. | |
DE60317884T8 (de) | Natriumkanalblocker | |
NO20021358D0 (no) | Alkylendiamin-substituerte heterocykler | |
DE3850676T2 (de) | Hypotensive okulare Mittel. | |
CA2351703A1 (en) | Novel 4-dedimethylaminotetracycline derivatives | |
NO20004053L (no) | Glukokortikoid-selektive antiinflammatoriske midler | |
DK1316801T3 (da) | Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer | |
DK1049700T3 (da) | Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf | |
FR2382460A1 (fr) | Complexe antigene proteine pour bloquer les reactions allergiques | |
TR200002345T2 (tr) | Glukokortikoit seçiçi antienflamatuar ajanlar | |
DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese | |
DK0642356T3 (da) | Antistoffer mod P-selectin og deres anvendelser | |
BR0110208A (pt) | Composições e terapias para distúrbios associados com hiperlipidemia | |
DE69427484T2 (de) | Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma | |
WO2001091796A8 (en) | Methods, compounds and compositions for treating gout | |
TR199801659T2 (xx) | Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�. | |
DK0788512T3 (da) | Proinsulinpeptidforbindelser til detektion og behandling af Type I-diabetes | |
EP0776650A3 (de) | Dentaladhäsive |